Medical Affairs Reputations: Type 2 Diabetes Mellitus (US)
|米国のメディカルアフェアーズの評価：2型糖尿病 (T2DM) Medical Affairs Reputations: Type 2 Diabetes Mellitus (US)|
|出版日: 2017年07月01日||ページ情報: 英文||
当レポートでは、2型糖尿病 (T2DM) 治療薬の主要10製品に関連するメディカルアフェアーズ (MA) チームについて米国国内の医師100名を対象に調査し、もっとも重要と考えるMAによる提供内容、もっとも尊重されているMAチームと他チームとの違い、MAによる提供内容への満足度、好みの伝達手段、改善の機会などについてまとめています。
Find out what the leading medical affairs teams in type 2 diabetes are doing right
Medical affairs teams for several leading T2DM treatments in the US seem to be ticking all the boxes in terms of interaction quality. Notwithstanding this, the diabetologists and primary care physicians we surveyed gave mixed views in terms of performance and satisfaction ratings; while some teams standout, others need to up their game. This report reveals how your team measures up, so you can learn from the successes, avoid the failures and build better relationships with physicians.
Learn what your team gets right, and where it's going wrong in Medical Affairs Reputations: Type 2 Diabetes Mellitus (US).
Comparing 11 major melanoma treatments from Novo Nordisk, Boehringer Ingelheim, Sanofi, Merck & Co., Johnson & Johnson, Eli Lilly, and AstraZeneca this report reveals:
Find out what more doctors want from your medical affairs team including:
That's actionable information you can use to turn your team into one that doctors rely on.
Insight into Medical Affairs Teams for These T2DM Treatments
An Expert-designed Competitive View of Your Medical Affairs Team
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 11 medical affairs teams-answering important questions like:
What do physicians need?
Does your medical affairs team deliver?
What needs improvement?
Based on Interviews with Practicing Doctors
We surveyed 100 US medical diabetologists and primary care physicians, chosen from the largest community of validated physicians in the world
We conducted the survey between July 3rd and July 12th, 2017.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.